IOL Chemicals & Pharmaceuticals Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1nga0d7gjwuiz7vh7912djmt.pdf

Key Takeaways


Demand & Pricing Environment

Abhay Raj Singh: "Earlier, we were expecting that there will be some relief from Q4 onwards. But I think now this is deferring by one more quarter."

Segment Performance

SegmentTrendCommentary
Chemicals▲ Volume, ▼ PriceVolume up >15% QoQ; revenue declined on lower realizations. Margins improved on stable raw material prices, operational efficiency, capacity utilization, and new market exploration including REACH-certified ethyl acetate exports to Europe.
Ibuprofen API▬ Stable, then softeningMargins stable and bottomed out for three quarters, but prices softened again in the last few days. Capacity utilization targeted to reach ~90% in the next two to three quarters.
Non-Ibuprofen API▲ Modest growth6% growth driven by Metformin and Pantoprazole. Client validation in European and Latin American markets is in process with trial orders and samples; better export prices expected to drive future revenue.
Acetic Anhydride▲ New contributorPlant commercialized last year; exports now beginning, which should fetch better prices.

Strategic Initiatives & Regulatory Progress


Margins & Cost Structure

Abhay Raj Singh: "So expectation is one thing. Estimate is another thing. So what we are estimating that from Q2 onwards we will find some or may be Q1 onwards, next year we will start seeing the improvement in the pricing pressures..."

Capital Management & Shareholder Returns


Competitive & External Risks

Abhay Raj Singh: "Do not have that much of idea. But the tariff is what the U.S. is saying that they will be reciprocating the tariff... That may impact, but indirectly, not directly."

Guidance & Commitments

CommitmentSpecificsTimeline
Ibuprofen capacity utilizationReach ~90%Next 2-3 quarters
New land facility ramp-upFacility operational18-24 months
EBITDA margin (company level)13% to 15%Not specified
Topline growth10% to 12%Considering current scenario
EBITDA margin target14% to 15%When prices recover
Double-digit operating profit marginImprovement beginsQ1 or Q2 FY26
Export share target40% to 45% of total revenueNot specified
Demand and pricing recoveryPick-up in pharma and chemical sectorFY26

Key Metrics

MetricQ3 FY25
Total standalone income₹527 cr, vs ₹529 cr in Q3 FY24 and ₹532 cr in Q2 FY25
EBITDA₹51 cr, vs ₹53 cr in Q3 FY24 and ₹48 cr in Q2 FY25
EBITDA margin9.7%, vs 10% in Q3 FY24 and 9% in Q2 FY25
Net profit₹21 cr, vs ₹23 cr in Q3 FY24 and ₹19 cr in Q2 FY25
EBIT margin, pharmaceutical segment8.7%
EBIT margin, specialty chemical segment2.1%
CAPEX₹54 cr, vs ₹80 cr in Q3 FY24 and ₹83 cr in Q2 FY25
Interim dividend₹4 per share (40% of face value ₹10), record date 18 Feb 2025
Stock split record date11 March 2025, face value sub-divided to ₹2 from ₹10
Ibuprofen capacity utilization~75%, targeting ~90% in next 2-3 quarters
Ibuprofen average price~$9, margins stable but prices softened in recent days
Volume growth, chemical sector>15% QoQ
Volume growth, API segment (Ibu and non-Ibu)~1-2%, almost stable
Non-Ibuprofen portfolio growth6% this quarter, driven primarily by Metformin and Pantoprazole
Chemical revenue₹275 cr, 4% decline due to price despite volume increase
Topline growth guidance10-12%, considering current scenario
EBITDA margin expectation, company as a whole13-15%
Export share target40-45% for the company as a whole